Tatva Chintan Pharma Chem Limited has informed the Exchange that Board of Directors at its meeting held on May 02, 2025, recommended Final Dividend of Re. 1 per equity share.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem Limited's Board of Directors, at its meeting on May 2, 2025, recommended a Final Dividend of Re. 1 (10%) per equity share of face value Rs. 10 each for FY 2024-25, subject to shareholder approval at the upcoming AGM. The company also announced its audited financial results, with consolidated revenue from operations of Rs. 3,827.14 million (slightly down from Rs. 3,935.04 million in FY24). Consolidated net profit fell sharply to Rs. 96.14 million from Rs. 303.54 million in FY24, a decline of about 68%, reflecting significant pressure on profitability. Standalone net profit also dropped to Rs. 82.47 million from Rs. 293.48 million. Additionally, the Board approved the appointment of M/s. TNT & Associates as Secretarial Auditor for 5 years (FY26-FY30), M/s. Zarna Thakar & Associates as Cost Auditor, and RSM Astute Consultech as Internal Auditor for FY 2025-26.
The modest final dividend of Re. 1 per share offers limited yield support to shareholders given the sharp year-on-year drop in profits. The steep earnings decline is likely to weigh on investor sentiment and could put pressure on the stock price in the short term.